Compare The Coca-Cola Co K (KO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Sana Biotechnology Inc — how do they compare? The Coca-Cola Co K trades at $81.93 (market cap $353.32B), while Sana Biotechnology Inc trades at $3.23 (market cap $873.84M). The key difference: The Coca-Cola Co K is far larger — about 404.3× Sana Biotechnology Inc's market cap, and The Coca-Cola Co K pays a 2.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KO | SANA | |
|---|---|---|
Market Cap | $353.32B | $873.84M |
Volume | 14,630,257 | — |
Sector | Consumer Staples | Health |
52-Week High | $84.92 | $5.92 |
52-Week Low | $65.67 | $2.68 |
Enterprise Value | $383.39B | $848.03M |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $81.87, up 0.38% today, with a neutral technical signal and strong fundamentals including a 27.8% net income margin and consistent earnings beats. The stock shows robust profitability with ROE at 45.8% and a dividend yield supported by 64 consecutive years of increases. Recent news highlights institutional buying and stable demand trends ahead of Q2 2026 earnings.
Outlook remains positive with a consensus price target of $90.67, implying ~11% upside. Risks include regional demand divergence and high debt levels. Analyst sentiment is bullish (60% Buy ratings), but investors should monitor execution against earnings expectations and macroeconomic pressures on consumer spending.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
